0001654954-20-007991.txt : 20200825 0001654954-20-007991.hdr.sgml : 20200825 20200724160139 ACCESSION NUMBER: 0001654954-20-007991 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GT Biopharma, Inc. CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 310 N. WESTLAKE BLVD. STREET 2: SUITE 206 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 BUSINESS PHONE: (800) 304-9888 MAIL ADDRESS: STREET 1: 310 N. WESTLAKE BLVD. STREET 2: SUITE 206 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 FORMER COMPANY: FORMER CONFORMED NAME: OXIS INTERNATIONAL INC DATE OF NAME CHANGE: 19940916 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 CORRESP 1 filename1.htm gtbp_corresp
 
VIA EDGAR AND ELECTRONIC MAIL
 
GT BIOPHARMA, INC.
9350 Wilshire Blvd. Suite 203
Beverly Hills, CA 90212
 
 
July 24, 2020
 
 
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
 
 
RE: GT Biopharma, Inc.
Registration Statement on Form S-1 (File No. 333-239858)
Request for Acceleration of Effective Date
 
 
Ladies and Gentlemen:
 
Pursuant to Rule 461 of the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-239858) and declare the Registration Statement effective as of July 28, 2020, at 4:00 p.m. (Eastern time), or as soon as practicable thereafter.
 
Please contact the undersigned at (800) 304-9888, or Michael Hamilton, Baker & McKenzie LLP, at (713) 427-5033, with any questions. Also, please notify Mr. Hamilton by telephone when this request for acceleration has been granted.
 
 
 
Very truly yours,
 
 
 
GT Biopharma, Inc.
 
 
 
 
 
By: /s/ Steven Weldon
 
Name: Steve Weldon
 
Title: Chief Financial Officer
 
 
cc:
Michael Hamilton
 
Baker & McKenzie LLP